Effect of Systemic Steroid Use for Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Receiving PD-1 Blockade Drugs

Objectives: Programmed death-1(PD-1)/programmed death ligand-1 (PD-L1) antibodies have clinical benefits for cancer patients facing immune-related adverse events (irAEs). However, the effect of steroid use on the prognosis of patients with non-small cell lung cancer (NSCLC) receiving PD-1 blockade r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kousuke, Miura, Yu, Shiono, Ayako, Shinomiya, Shun, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397225/
https://www.ncbi.nlm.nih.gov/pubmed/34442054
http://dx.doi.org/10.3390/jcm10163744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397225/
https://www.ncbi.nlm.nih.gov/pubmed/34442054
http://dx.doi.org/10.3390/jcm10163744

Ejemplares similares